1 Secondary end points were a 50% or greater reduction in mean
2 Secondary end points were all-cause death, nonfatal AMI, reho
3 Secondary end points were all-cause mortality within 180 days
4 Secondary end points were binary restenosis, target lesion re
5 Secondary end points were breast cancer mortality and distant
6 Secondary end points were change in 6-minute walk distance, p
7 The
secondary end points were changes in device settings.
8 Secondary end points were components of the primary end point
9 Secondary end points were consistently improved in the VR-CAP
10 Secondary end points were CR rate, overall survival (OS), qua
11 No significant effects on the
secondary end points were discernable.
12 The primary end point was overall survival (OS),
secondary end points were disease control-progression-free su
13 The main end point was overall survival (OS);
secondary end points were disease-free survival (DFS) and spe
14 Secondary end points were diurnal IOP measurements at months
15 Secondary end points were event-free survival, overall surviv
16 Secondary end points were frequency of infections, treatment-
17 Predefined
secondary end points were global QOL (GQOL; QLQ-C30), fatigue
18 Secondary end points were in-hospital/30-day mortality for th
19 Secondary end points were inappropriate anti-tachycardia paci
20 Secondary end points were left ventricular function and volum
21 Secondary end points were objective response rate by immune-r
22 Secondary end points were overall survival (OS), progression-
23 Secondary end points were overall survival (OS), tumor respon
24 Main
secondary end points were overall survival and bronchiolitis
25 d point was 5-year disease-free survival (DFS), and the key
secondary end points were overall survival and safety.
26 Secondary end points were overall survival, objective respons
27 Secondary end points were:
overall response rate, stem-cell m
28 Secondary end points were patient-reported toxicity, overall
29 Secondary end points were preirradiation response rates, prog
30 Primary end point was overall survival (OS), and
secondary end points were progression-free survival (PFS), re
31 primary end points were safety and objective response rate;
secondary end points were progression-free survival and overa
32 Main Outcomes and Measures: Primary and
secondary end points were progression-free survival and overa
33 Secondary end points were rescue neuroleptic use, delirium re
34 res: Primary end point was progression-free survival (PFS);
secondary end points were response rate and overall survival
35 he primary end point was 6-month progression-free survival;
secondary end points were response rate, overall survival, qu
36 Key
secondary end points were rhinitis symptoms, medication score
37 Secondary end points were serum iPTH concentration, serum pho
38 The key
secondary end points were T-cell persistence and their antigl
39 If noninferiority of degludec/liraglutide was achieved,
secondary end points were tested for statistical superiority
40 Secondary end points were the change in the mean number of mu
41 Secondary end points were the disease control rate (DCR) at w
42 Secondary end points were the incidence of binary in-stent re
43 end point was a composite of rebleeding and death, and main
secondary end points were the individual components of the co
44 Secondary end points were the number of telephone calls and e
45 Secondary end points were the rate of nocturnal symptomatic h
46 The
secondary end points were the rate of sickle cell-related pai
47 Secondary end points were the rates of operative success and
48 Secondary end points were the scores for working memory (scor
49 Secondary end points were the time to a new exacerbation and
50 The
secondary end points were time to progression, progression-fr